DEBORAH DE SA PEREIRA BELFORT
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Venous Thromboembolism as an Initial Manifestation of COVID-19 in a Heart Transplant Patient(2021) DANTAS, R. C. Tourinho; LIRA, M.; BELFORT, D.; ARAGAO, C.; MURAD, C.; AVILA, M.; SEGURO, L.; MANGINI, S.; CAMPOS, I.; MARCONDES-BRAGA, F.; BACAL, F.conferenceObject Early Antibody-Mediated Rejection in Non-Pre-Sensitized Heart Transplant Recipient(2021) LIRA, M. S.; BELFORT, D. Sa Pereira; DANTAS, R. Cavalcanti Tourinho; ARAGAO, C. Aurelio Santos; AVILA, M. Samuel; SEGURO, L.; MANGINI, S.; CAMPOS, I. Wozniak; MARCONDES-BRAGA, F.; BACAL, F.conferenceObject Characteristics and Outcomes of Heart Transplant Recipients with Coronavirus-19 Disease(2021) MARCONDES-BRAGA, F. G.; MURAD, C. M.; BELFORT, D. D.; DANTAS, R. C.; LIRA, M. S.; ARAGAO, C.; SICILIANO, R. F.; MANGINI, S.; SEGURO, L.; CAMPOS, I. W. de; AVILA, M. S.; BELLO, M. V.; BARONE, F.; STRABELLI, T. M.; GAIOTTO, F. A.; BACAL, F.- Aortic and Renal Artery Thrombosis as the First Clinical Manifestation of COVID-19 in a Heart Transplant Recipient(2021) BELFORT, Deborah de Sa Pereira; MARCONDES-BRAGA, Fabiana G.; MANGINI, Sandrigo; CAFEZEIRO, Caio Reboucas Fonseca; FURLAN, Diogenes Amauri Goncalves; BACAL, Fernando
conferenceObject Aortic and Renal Artery Thrombosis as the First Clinical Manifestation of COVID-19 in a Heart Transplant Recipient(2021) BELFORT, D. S.; CAFEZEIRO, C. R.; FURLAN, D. A.; LIRA, M. S.; DANTAS, R. C.; ARAGAO, C. A.; CAMPOS, I. W.; AVILA, M. S.; MANGINI, S.; SEGURO, L. B.; MARCONDES-BRAGA, F. G.; BACAL, F.conferenceObject Necropsy findings in heart transplant recipients with and without primary graft dysfunction: a retrospective study(2023) BELFORT, D. S. P.; MANGINI, S.; AVILA, M. S.; MARCONDES-BRAGA, F. G.; CAMPOS, I. W.; SEGURO, L. F. B. C.; BACAL, F.; GUTIERREZ, P. S.conferenceObject Neurochagas: A Rare Case of Reactivation of Chagas Disease after Heart Transplantation(2021) ARAGAO, C. A.; CAMPOS, I. W.; DANTAS, R. T.; LIRA, M. T.; BELFORT, D. S.; MURAD, C. M.; AVILA, M. S.; SEGURO, L. F.; MANGINI, S.; STRABELLI, T. V.; BRAGA, F. M.; BACAL, F.conferenceObject Change in the Clinical-Demographic Profile of Chagasic Patients Who are Candidates for Heart Transplantation in Recent Years(2021) ARAGAO, C. A.; CAMPOS, I. W.; LIRA, M. T.; DANTAS, R. T.; MURAD, C. M.; BELFORT, D. S.; MANGINI, S.; STRABELLI, T. V.; BRAGA, F. M.; SEGURO, L. F.; AVILA, M. S.; GAIOTTO, F. A.; BACAL, F.- Characteristics and Outcomes of Heart Transplant Recipients With Coronavirus-19 Disease in a High-volume Transplant Center(2022) MARCONDES-BRAGA, Fabiana G.; MURAD, Ciro M.; BELFORT, Deborah S. P.; DANTAS, Rafael C. T.; LIRA, Maria Tereza S. S.; ARAGAO, Carlos A. S.; SICILIANO, Rinaldo F.; MANGINI, Sandrigo; SEGURO, Luis Fernando B. C.; CAMPOS, Iascara W.; AVILA, Monica S.; BELLO, Mariana V. O.; SANTOS, Fernanda B. A. dos; V, Tania M. Strabelli; GAIOTTO, Fabio A.; BACAL, FernandoBackground. Heart transplant (HT) recipients may be at higher risk of acquiring SARS-CoV-2 infection and developing critical illness. The aim of this study is to describe characteristics and outcomes of HT recipients infected by SARS-COV-2, from a high-volume transplant center. Methods. We have described data of all adult HT recipients with confirmed coronavirus disease 2019 by RT-PCR in nasopharyngeal samples from April 5, 2020, to January 5, 2021. Outcomes and follow-up were recorded until February 5, 2021. Results. Forty patients were included. Twenty-four patients (60%) were men; the median age was 53 (40-60) y old; median HT time was 34 mo; and median follow-up time 162 d. The majority needed hospitalization (83%). Immunosuppressive therapy was reduced/withdrawn in the majority of patients, except from steroids, which were maintained. Seventeen patients (42.5%) were classified as having severe disease according to the ordinal scale developed by the World Health Organization Committee. They tended to have lower absolute lymphocyte count (P < 0.001) during follow-up when compared with patients with mild disease. Thirty-day mortality was 12.5%. However, a longer follow-up revealed increased later mortality (27.5%), with median time to death around 35 d. Bacterial nosocomial infections were a leading cause of death. Cardiac allograft rejection (10%) and ventricular dysfunction (12.5%) were also not negligible. Conclusions. Major findings of this study corroborate other cohorts' results, but it also reports significant rate of later events, suggesting that a strict midterm surveillance is advisable to HT recipients with coronavirus disease 2019.